Back to search

Article

Novel Synthetic Promoter Armed Oncolytic Herpes Simplex Virus For Treatment of PAX3-FOXO1 Positive Rhabdomyosarcoma

2026-06-12

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Due to the difficulty in targeting oncogenic transcription factors, there are no targeted treatments available for pediatric patients afflicted with PAX3-FOXO1 fusion positive alveolar rhabdomyosarcoma. Additionally, alveolar rhabdomyosarcomas are immunologically cold tumors inherently resistant to immune checkpoint blockade. Viral vectors present a unique opportunity to add...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7e065efb-2864-5e09-baa6-b12f722a2195
DOI
10.64898/2026.06.09.731216
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel Synthetic Promoter Armed Oncolytic Herpes Simplex Virus For Treatment of PAX3-FOXO1 Positive RhabdomyosarcomaDOI 10.64898/2026.06.09.731216
Select a neighboring publication to make it the new centre.